Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL.
A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- ClinicalTrials.gov Identifier: NCT03534323
- Protocol Number: 18-089
- Principal Investigator: Jon Arnason
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required